In the original article, there was error in Table 1 as published. The probiotic efficacy for Emara 2014 and Francavilla 2014 reported a significant increase instead of a non-significant increase.
Table 1
| Treatment | Probiotic(s) | Eradication rate | Probiotic efficacy | References |
|---|---|---|---|---|
| Triple therapy, Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, 14 d | L. reuteri ATCC PTA 6475, L. reuteri DSM 17938, 14 d during therapy + further 14 d, Control | 74.3% (26/35) 65.7% (23/35) | Non-significant increase of eradication rate with improved GSRS score and reduction of side effects (taste disorder, diarrhea) | Emara et al., 2014 |
| Three-phase study; pre-eradication (1–28 d), eradication (29–35 d), follow-up (36–96 d), Triple therapy | L. reuteri ATCC PTA 6475, L. reuteri DSM 17938, Control | 75% (37/50) 65.9% (33/50) | Non-significant increase of eradication rate but no difference in GSRS score | Francavilla et al., 2014 |
| Pantoprazole 20 mg, 8 weeks | L. reuteri, 8 weeks | 14.2% (3/21) | Good tolerability with no side effects | Dore et al., 2014 |
| Levofloxacin 500 mg, esomeprazole 20 mg, amoxicillin 1 g, 7 d | L. reuteri, during therapy + further 7 d Control | 80% (36/45) 62.2% (28/45) | Significantly increase of eradication rates and reduction of side effects (Nausea, diarrhea) | Ojetti et al., 2012 |
| Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, 7 d | L. plantarum, L. reuteri, L. casei subsp. rhamnosus, B. infantis, and B. longum, L. acidophilus, L. salivarius, S. thermophilus, L. sporogenes, during therapy Control | 82.2% (30/34) 76.4% (26/34) | Non-significant increase of eradication rates; significant reduction of side effects (epigastric pain, nausea, vomiting, diarrhea) | Tolone et al., 2012 |
| Pantoprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, Triple therapy, 7 d Sequential regimen, 10 d | L. reuteri ATCC55730, during therapy + further 7 or 10 d | 63% (52/83) 88% (73/83) | Significantly higher eradication rate and reduction of side effects in sequential regimen | Efrati et al., 2012 |
| Sequential therapy (Details not describe) | L. reuteri ATCC55730, 8 weeks Control | 33.8 ± 15% (33) 35.8 ± 15.5% (33) | Significant decrease in Gastrointestinal Symptom | Francavilla et al., 2008 |
| Triple therapy (Details not describe) | L. reuteri, 7 d Control | 63% 53% | Lowest incidence of side-effects | Scaccianoce et al., 2008 |
| No drug | L. reuteri SD2112, 8 weeks | 69.7 ± 4% (33) | Significant reduction of 13C-UBT | Imase et al., 2007 |
| Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, sequential therapy, 10 d | L. reuteri ATCC55730 (SD2112) Control | 85% (17/20) 80% (16/20) | Significant reduction of GSRS score | Lionetti et al., 2006 |
Selected clinical trials using Lactobacillus reuteri for H. pylori eradication treatment.
GSRS, Gastrointestinal Symptom Rating Scale; 13C-UBT; 13C Urea Breath Test.
Additionally, the reference for “Francavilla et al., 2008” in Table 1 was incorrectly written as “Francavilla, R., Lionetti, E., and Cavallo, L. (2008). Sequential treatment for Helicobacter pylori eradication in children. Gut 57:1178.” It should be “Francavilla, R., Lionetti, E., Castellaneta, S. P., Magistà, A. M., Maurogiovanni, G., Bucci, N., et al. (2008). Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter 13, 127–134. doi: 10.1111/j.1523-5378.2008.00593.x”.
The corrected Table 1 and Reference appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
References
1
DoreM. P.CuccuM.PesG. M.MancaA.GrahamD. Y. (2014). Lactobacillus reuteri in the treatment of Helicobacter pylori infection. Intern. Emerg. Med.9, 649–654. 10.1007/s11739-013-1013-z
2
EfratiC.NicoliniG.CannavielloC.O'sedN. P.ValabregaS. (2012). Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. World J. Gastroenterol.18, 6250–6254. 10.3748/wjg.v18.i43.6250
3
EmaraM. H.MohamedS. Y.Abdel-AzizH. R. (2014). Lactobacillus reuteri in management of Helicobacter pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap. Adv. Gastroenterol.7, 4–13. 10.1177/1756283X13503514
4
FrancavillaR.LionettiE.CastellanetaS. P.MagistàA. M.MaurogiovanniG.BucciN.et al. (2008). Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter13, 127–134. 10.1111/j.1523-5378.2008.00593.x
5
FrancavillaR.PolimenoL.DemichinaA.MaurogiovanniG.PrincipiB.ScaccianoceG.et al. (2014). Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study. J. Clin. Gastroenterol.48, 407–413. 10.1097/MCG.0000000000000007
6
ImaseK.TanakaA.TokunagaK.SuganoH.IshidaH.TakahashiS. (2007). Lactobacillus reuteri tablets suppress Helicobacter pylori infection–a double-blind randomised placebo-controlled cross-over clinical study. Kansenshogaku Zasshi81, 387–393. 10.11150/kansenshogakuzasshi1970.81.387
7
LionettiE.MinielloV. L.CastellanetaS. P.MagistáA. M.de CanioA.MaurogiovanniG.et al. (2006). Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment. Pharmacol. Ther.24, 1461–1468. 10.1111/j.1365-2036.2006.03145.x
8
OjettiV.BrunoG.AinoraM. E.GiganteG.RizzoG.RoccarinaD.et al. (2012). Impact of Lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol. Res. Pract.2012:740381. 10.1155/2012/740381
9
ScaccianoceG.ZulloA.HassanC.GentiliF.CristofariF.CardinaleV.et al. (2008). Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur. Rev. Med. Pharmacol. Sci.12, 251–256.
10
ToloneS.PellinoV.VitalitiG.LanzafameA.ToloneC. (2012). Evaluation of Helicobacter Pylori eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. Ital. J. Pediatr.38:63. 10.1186/1824-7288-38-63
Summary
Keywords
Lactobacillus reuteri, Helicobacter pylori, probiotics, inflammation, triple therapy
Citation
Tyagi AK and Prasad S (2019) Corrigendum: Commentary: Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front. Microbiol. 10:1628. doi: 10.3389/fmicb.2019.01628
Received
02 April 2019
Accepted
02 July 2019
Published
18 July 2019
Volume
10 - 2019
Edited and reviewed by
Fabio Minervini, University of Bari Aldo Moro, Italy
Updates
Copyright
© 2019 Tyagi and Prasad.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Amit K. Tyagi akumar6@mdanderson.org; amittyagiiitd@gmail.com
This article was submitted to Food Microbiology, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.